PARP 抑制剂的作用机制及其在前列腺癌中的应用

参考文献：

[1] 朱耀,韦煜,潘剑,等. PARP抑制剂在同源重组修复基因突变型前列腺癌中的临床研究进展.中华泌尿外科杂志,2021，42(05) : 397-397.

[2] 中华医学会病理学分会，中华医学会泌尿外科学分会，国家病理质控中心. 前列腺癌同源重组修复基因检测及变异解读专家共识. 中华病理学杂志，2022，51(10):941-949.

[3] Dong B, Fan L, Yang B, et al. Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study. J Natl Compr Canc Netw. 2021;19(8):905-914. Published 2021 May 14.

[4] Castro E, Romero-Laorden N, Del Pozo A, et al. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019;37(6):490-503.

[5] Piombino C, Pipitone S, Tonni E, et al. Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities. Int J Mol Sci. 2024;25(9):4624. Published 2024 Apr 24.

[6] Mateo J, de Bono JS, Fizazi K, et al. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. J Clin Oncol. 2024;42(5):571-583. 

[7] de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382(22):2091-2102.

[8] Abida W et al. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. Eur Urol. 2023 Sep;84(3):321-330.

[9] Matthew R Smith，et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial[J].Lancet Oncol. 2022 Mar;23(3):362-373

[10] Johann S de Bono,et al. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial[J]. Lancet Oncol. 2021 Sep;22(9):1250-1264.